CD8A and neoplasm: Combined with anti-PD-L1 therapy, more CD8+ and CD4+ T cells were produced, which extended the survival period of mice and enhanced the checkpoint blockade therapy of anti-PD-1/PD-L1 with no response to CRC.461,462 Huang et al. prepared a pH-responsive lipid of dendritic polymers-calcium phosphate (TT-LDCP) NPS modified with tumor targeting peptide (SP94), which carried the immunosuppressive factor of small interfering RNA (siRNA) and encoded immune stimulation cytokines IL-2 plasmid DNA (pDNA).